

## KALC-IC 2022 [Free Paper: Oral Presentation]

Abstract No.	Presentation No.	Time	Subject	Presenting Author	
				Name	Institution
<b>November 10, 2022</b>					
86	O1-1	10:30-10:40	Exosome-GCC2 as a Promising Biomarker and Therapeutic Target for Lung Adenocarcinoma: a Multicenter study	Byeong Hyeon Choi	Korea University
43	O1-2	10:40-10:50	AXL Affects Tumor Growth of Lung Cancer through Regulating of Dendritic Cells	Kyungtaek Im	Asan Institute for Life Sciences
67	O1-3	10:50-11:00	The Expression of CEACAMs and Serum CEA Levels as Biomarkers of Postoperative Cancer Recurrence in Non-small Cell Lung Cancer	Bubse Na	Seoul National University
88	O1-4	11:00-11:10	Plasma GDF15 Levels Are Associated with PD-1+ T Cells in Advanced NSCLC Patient Who Treated Immunotherapy	Da Hyun Kang	Chungnam National University
64	O1-5	11:10-11:20	Preoperative Mediastinal Lymph Node Evaluation with Cancer-Associated Fibroblast Imaging Using Ga-68 FAPI PET/CT in Non-Small Cell Lung Cancer: A Prospective Pilot Study	Kwon Joong Na	Seoul National University
84	O1-6	11:20-11:30	Augmented Reality Eye Glasses Display for Real-Time Fluorescent Imaging-Guided Surgery	Ok Hwa Jeon	Korea University
78	O1-7	11:30-11:40	The 10-Year Journey of Non-Small Cell Lung Cancer: Real-World Experience	Daeho Choi	Sungkyunkwan University
52	O1-8	11:40-11:50	Application of Exosomal miRNAs as Diagnosis Biomarkers for Small Cell Lung Cancer	Dong Ha Kim	Asan Institute for Life Sciences
<b>November 11, 2022</b>					
85	O2-1	10:30-10:40	Long-Term Surgical Outcomes of Oligometastatic Non-Small-Cell Lung Cancer: A Single-Center Study	Seungmo Yoo	University of Ulsan
81	O2-2	10:40-10:50	Existence of Pre-operative Clonal Hematopoiesis Is Related to Adverse Outcome in Surgically Resected Non-Small Cell Lung Cancer Patients Who Underwent Adjuvant Therapy	Jae Kwang Yun	University of Ulsan
79	O2-3	10:50-11:00	Longitudinal Monitoring of Circulating Tumor DNA from Plasma in Patients with Curative Resected Stage IA-IIIa EGFR Mutant-Non-Small Cell Lung Cancer	Hyun Ae Jung	Sungkyunkwan University
107	O2-4	11:00-11:10	Risk Prediction of Multiple-station N2 Metastasis in Patients with Clinical Single-station N2 NSCLC	Joon Young Kim	University of Ulsan
93	O2-5	11:10-11:20	Different Prognostic Impact between Single-Zone and Multiple-Zone N2 Node Metastasis in Patients with N2b NSCLC	Shia Kim	University of Ulsan
8	O2-6	11:20-11:30	Lobectomy Versus Sublobar Resection for Stage I (T1-T2aNoMo) Small Cell Lung Cancer: A SEER Population-Based Propensity Score Matching Analysis	Ning Zhou	Tianjin Medical University
65	O2-7	11:30-11:40	Clinical Outcome of Stereotactic Body Radiotherapy in Early-Stage Lung Cancer Patient with Ground Glass Opacity Predominant Lesion: A Single Institution Experience	Jeong Yun Jang	University of Ulsan
109	O2-8	11:40-11:50	Oncologic Outcomes of Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease	Young Seob Shin	University of Ulsan
<b>November 11, 2022</b>					
49	O3-1	13:00-13:10	Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients from VISION Cohorts A and C	Myung-Ju Ahn	Sungkyunkwan University
77	O3-2	13:10-13:20	The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer	Hyun Ae Jung	Sungkyunkwan University
42	O3-3	13:20-13:30	Evaluation of Blood Tumor Mutation Burden for Efficacy of Second-Line Atezolizumab Treatment in Non-Small Cell Lung Cancer: BUDDY Trial	Cheol-Kyu Park	Chonnam National University
97	O3-4	13:30-13:40	Distinct Characteristics and Treatment Outcomes of Exon20 Insertion Mutations Positive Non-Small Cell Lung Cancer Patients in Real World Practice	Mi Sook Kim	National Cancer Center
46	O3-5	13:40-13:50	AdvanTIG-105; Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC	Se Hyun Kim	Seoul National University
14	O3-6	13:50-14:00	Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer	Jang Ho Lee	University of Ulsan
48	O3-7	14:00-14:10	Tepotinib in Asian Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping	Ji-Youn Han	National Cancer Center
72	O3-8	14:10-14:20	Application of Machine Learning Algorithms for the Prediction of Afatinib Treatment Outcome in Advanced Stage EGFR-Mutated NSCLC	Taeyun Kim	The Armed Forces Goyang Hospital
23	O3-9	14:20-14:30	AdvanTIG-105; Phase 1b Dose-Expansion Study of Ociperlimab+Tislelizumab with Chemotherapy in Patients with Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer	Hye Ryun Kim	Yonsei University
47	O3-10	14:30-14:40	Clinical Response to Tepotinib according to Circulating Tumor (ct)DNA Biomarkers in Patients with Advanced NSCLC with High-Level MET Amplification	Jin-Hyoung Kang	The Catholic University of Korea